ATGListatin and pharmaceutical composition comprising the same
US9206115B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 23, 2014 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Jan 23, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/44
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A compound of formula (I) as defined hereinis useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.